The death of tech was excessively premature
In the long rhythm of markets and medicine, Thursday reminded investors that hope and reality seldom move at the same pace. A week after Pfizer's vaccine announcement briefly lifted spirits and reshuffled portfolios, the weight of 152,000 daily infections, stalled stimulus talks, and the slow machinery of vaccine distribution pulled U.S. equities back toward caution. The gap between what is possible and what is imminent proved, once again, to be where markets find their humility.
- A record 152,000 COVID-19 cases in a single day shattered the optimism that had briefly sent markets soaring on vaccine news, reminding investors the virus was accelerating faster than any cure could reach arms.
- The swift rotation from technology into value and cyclical stocks — one of the sharpest in years — began to reverse as analysts warned the trade had moved too far, too fast on a vaccine still months from widespread distribution.
- With the Trump administration stepping back from stimulus negotiations and leaving Congress to bridge a widening divide, the economic lifeline that 21 million unemployed Americans were counting on remained frustratingly out of reach.
- By the closing bell, the Dow had shed 319 points, gold climbed as a safe haven, and Treasury yields fell — the market's quiet admission that uncertainty, not optimism, was once again setting the tone.
Thursday's trading session ended the stock market's brief romance with vaccine optimism. The Dow fell 319 points, the S&P 500 dropped 1%, and even the Nasdaq — which had surged earlier in the week — slipped modestly. The catalyst for the retreat was impossible to ignore: the United States had recorded more than 152,000 new COVID-19 cases in a single day, a record, while hospitalizations and death rates continued to climb. The seven-day average for new infections had more than doubled in a month.
The Pfizer vaccine announcement earlier in the week had sparked a powerful rally and a dramatic rotation out of technology stocks into value and cyclical plays — the kind of companies that would benefit most from a reopened economy. But that momentum faded quickly as investors confronted the uncomfortable arithmetic of vaccine distribution. Approval and widespread rollout remained months away at minimum, and in the interim, the threat of new lockdowns loomed over a recovery still finding its footing. Goldman Sachs economist Jan Hatzius flagged the resurgence as a key risk to growth, warning that consumer behavior could deteriorate sharply if case counts kept rising.
Not everyone was ready to abandon technology. BMO Capital Markets strategist Brian Belski argued that with growth uncertain and lockdown risks elevated, the stay-at-home trade remained a defensible position — the rotation into value, he suggested, had been overdone.
Beyond the virus, stimulus negotiations had stalled after the Trump administration stepped back, leaving McConnell and Pelosi to work out the details. The labor market offered mixed signals: jobless claims fell to 709,000, better than expected, but still more than three times the pre-pandemic weekly average. More than 21 million Americans remained on some form of unemployment support.
By the close, the Dow settled at 29,078.99, gold rose to $1,873.90 as investors sought safety, and the 10-year Treasury yield fell to 0.8850%. What the day made plain was that the vaccine rally had rested on an assumption markets were now being forced to revisit — that relief was close enough to price in. The virus, still spreading at record pace, was offering no such assurance.
The stock market's brief flirtation with optimism came to an abrupt end on Thursday. The Dow fell 319 points, the S&P 500 dropped 1%, and the Nasdaq managed only a slight decline as investors confronted a widening gap between hope and reality. The hope had arrived earlier in the week when Pfizer announced its vaccine candidate was more than 90% effective, sparking a powerful rally and a sudden rotation out of technology stocks into value and cyclical plays. That momentum evaporated as the week wore on, undone by a simple fact: the virus was winning.
On Wednesday alone, the United States recorded more than 152,000 new COVID-19 cases—a record. The seven-day average for daily new infections had climbed to more than 130,000, more than double the figure from a month prior. Hospitalizations were surging. Death rates were rising. The pandemic had tightened its grip on the world's largest economy at precisely the moment when markets had begun to believe an escape route was in sight.
The problem was timing. Even if a vaccine could be approved and distributed, it would take months—several more months, at minimum. In the interim, the virus threatened to impose new lockdowns, state-wide or nationwide, that would choke off the fragile economic recovery still rebounding from the spring shutdowns. Goldman Sachs economist Jan Hatzius warned that the resurgence posed a key risk to growth, noting that while consumers had shown less voluntary caution during this wave than during the first surge, that restraint could evaporate if case counts, hospitalizations, and deaths continued their climb.
The market's swift pivot from technology to value stocks had been, in the view of some analysts, overdone. Brian Belski, chief investment strategist at BMO Capital Markets, pushed back against the narrative of tech's demise. Coming out of a recession, with growth uncertain over the next few quarters and the heightened likelihood of additional lockdowns, technology stocks and the stay-at-home trade remained defensible positions. The death of tech, he said, was premature.
Beyond the virus, investors were also digesting uncertainty around stimulus. The Trump administration had pulled back from negotiations over a new spending package, leaving the work to Congress—to Senate Majority Leader Mitch McConnell and House Speaker Nancy Pelosi. The labor market, meanwhile, offered mixed signals. Initial jobless claims fell to 709,000 for the week, better than the 731,000 economists had expected, but the number remained more than three times higher than the weekly average from 2019. More than 21 million Americans were still drawing unemployment benefits of some form.
Consumer prices had been flat in October, unchanged from September after a 0.2% rise the month before. Food away from home had climbed 0.3% month-over-month and 3.9% year-over-year as diners began returning to reopened restaurants. Energy prices, by contrast, had fallen another 0.5%, the fourth decline in seven months, as travel demand remained anchored by the pandemic. Excluding food and energy, the consumer price index was flat month-over-month and up just 1.6% year-over-year.
By the close of trading, the Dow had shed 319 points to 29,078.99. The S&P 500 fell to 3,536.99, down 1%. The Nasdaq, which had risen 2% on Wednesday, managed to hold closer to flat, down just 0.65%. Gold rose $12.30 per ounce to $1,873.90, a safe-haven move. Crude oil fell $0.44 to $41.01 a barrel. The 10-year Treasury yield dropped 7.3 basis points to 0.8850%.
What had become clear by day's end was that the vaccine rally, for all its power, had been built on an assumption the market was now forced to reckon with: that the path from laboratory to arm would be swift enough to matter in the near term. The virus, meanwhile, was not waiting.
Citações Notáveis
The death of tech was excessively premature. Coming out of a recession and questioning what growth will look like over the next couple of quarters, with higher likelihood of additional lockdowns, puts increased confidence in technology stocks.— Brian Belski, BMO Capital Markets chief investment strategist
The virus resurgence poses a key risk to the growth outlook. New lockdowns would jeopardize growth that's still rebounding from spring restrictions.— Jan Hatzius, Goldman Sachs economist
A Conversa do Hearth Outra perspectiva sobre a história
Why did the market turn so sharply? The vaccine news seemed genuinely good.
It was good, but it was also a mirage about timing. A 90% effective vaccine is wonderful—if you can get it into people's arms. But we're talking months away from approval, then months more for distribution. The virus isn't waiting for that timeline.
So the market was pricing in an immediate recovery?
Not consciously, maybe. But the rotation out of tech into value stocks—that was a bet that the economy would snap back quickly, that people would stop hiding at home and start flying and dining out again. When case counts hit 152,000 in a single day, that bet looked reckless.
What about the stimulus? That seemed like a separate problem.
It was. The administration stepped back from negotiations, which meant Congress had to figure it out. That's slower, messier, less certain. You had investors staring at rising infections, rising deaths, and now uncertainty about whether Washington would prop up demand. That's a lot of headwinds at once.
The labor market data came in better than expected, though.
It did, but it was still terrible in absolute terms. 709,000 new claims in a week. That's three times the pre-pandemic normal. And 21 million people still on benefits. Better than feared isn't the same as good.
Where does this leave investors?
Confused, probably. The vaccine is real and it works. But the near-term reality is more lockdowns, more deaths, more economic pain. The market had gotten ahead of itself. Now it's trying to figure out what the world actually looks like between now and when vaccines are widely available.